Research Article

Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats

Huiying Huang,1 Xiaohui Bai,2,3 Kun Zhang,2 Jin Guo,2 Shaoyong Wu,2 and Handong Ouyang2

1Department of Blood Transfusion, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, Guangdong, China
2Department of Anesthesiology, State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
3Department of Anesthesiology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Correspondence should be addressed to Shaoyong Wu; wushy@sysucc.org.cn and Handong Ouyang; ouyhd@sysucc.org.cn

Received 1 September 2021; Revised 10 March 2022; Accepted 20 April 2022; Published 18 May 2022

Academic Editor: Vahid Rakhshan

Copyright © 2022 Huiying Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Pentazocine produces a wide variety of actions in the treatment of perioperative analgesia. Neostigmine is a cholinesterase inhibitor used to antagonize the residual effects of muscle relaxants and also produces an analgesic effect. Objectives. To investigate the analgesic effects of intrathecally injected pentazocine and neostigmine and their interaction. Methods. Sprague–Dawley rats were used to test the analgesic effect of pentazocine and neostigmine using the paw formalin pain model and the incision mechanical allodynia model. Pentazocine (3, 10, 30, and 100 μg), neostigmine (0.3, 1, 3, and 10 μg) or a pentazocine-neostigmine mixture were separately injected to evaluate their antinociceptive effects alone on the treatment groups. The corresponding control group received an intrathecal injection containing the same volume of saline. The formalin pain test, or the plantar incision pain behavior test were performed 30 minutes later. Isobolographic analysis was used to evaluate the interaction between pentazocine and neostigmine. Intrathecally administered selective mu-opioid receptor antagonist CTAP, selective kappa-opioid receptor antagonist nor-Binaltorphimine (nor-BNI), nonselective opioid receptor antagonist naloxone, and muscarinic acetylcholine receptor antagonist atropine were also used to test the possible interaction mechanism. These antagonists were used 30 minutes before the pentazocine and neostigmine mixtures which were intrathecally injected. Results. Intrathecally administered pentazocine (3, 10, 30, and 100 μg) and neostigmine (0.3, 1, 3, and 10 μg) alone had a marked dose-related impact on suppressing the biphasic responses in the formalin test. Pentazocine (3, 10, 30, and 100 μg) and neostigmine (0.3, 1, 3, and 10 μg) alone attenuated the mechanical allodynia in a plantar incision model in a dose-dependent manner. Isobolographic analysis revealed that the mixture of intrathecal pentazocine and neostigmine synergistically decreased both phase I and II activity in the formalin test and mechanical allodynia in the plantar incision model. Pretreatment of intrathecally administered nor-BNI, naloxone, atropine, but not CTAP, antagonized the analgesic effect of the pentazocine-neostigmine mixture. Conclusions. All of these results suggest that the combined application of pentazocine and neostigmine is an effective way to relieve pain from formalin and acute incision mechanical allodynia. The synergistic effect between pentazocine and neostigmine is mostly attributed to the kappa-opioid receptor and the cholinergic receptor in the spinal cord.
1. Introduction

Pentazocine was previously classified as a kappa-opioid receptor agonist and a mu-opioid receptor antagonist, but researchers later determined it as a mixed kappa-opioid receptor agonist and a partial mu-opioid receptor agonist [1–3]. It shares lots of the side effects of other opioids such as constipation and nausea, but it produces less central nervous system depression. While it seldom affects the mood after short-term use, it sometimes causes hallucinations, nightmares, and delusions [4]. Intravenously administered pentazocine can reduce both the incidence and severity of itching in women treated with subarachnoid opioids during cesarean section [5]. Pentazocine is also effective in alleviating postoperative pain and is commonly used as an analgesic in the perioperative period [6]. Three major opioid receptor systems, mu-opioid, delta-opioid, and kappa-opioid have been characterized commonly used as an analgesic in the perioperative period and are also effective in alleviating postoperative pain and is used in the treatment of neuropathic pain, as well as underscore mPFC related cognitive shortfalls related to such pain [16]. In the process of anesthetic resuscitation, pentazocine is sometimes used as an analgesic, and neostigmine as a muscle relaxant antagonist. However, there is no research on the combined effects of pentazocine and neostigmine for postoperative pain treatment. In this experiment, the actual effects of pentazocine and neostigmine were assessed using a formalin-induced pain model and the plantar incisional pain model. To explore its possible mechanism of action, we intrathecally administered the selective kappa-opioid receptor antagonist nor-Binaltorphimine, the selective mu-opioid receptor antagonist CTAP, the nonselective opioid receptor antagonist naloxone, and the muscarinic acetylcholine receptor antagonist atropine.

2. Materials and Methods

2.1. Animals and Drug Administration. This research was approved by the Animal Care and Use Committee of Sun Yat-Sen University (No. L10202020000X, Guangzhou, China). Three hundred and eighty male Sprague–Dawley (SD) rats weighing 200 to 250 g were used. Rats were kept in separate cages with 50 to 60% humidity at 24°C with free access to food and water. All surgical procedures were performed with the rats under isoflurane (1–3%) inhalation. Nor-Binaltorphimine 10 μg (nor-BNI, Abcam ab120078), CTAP 10 μg (R&D, 1560/1), naloxone 10 μg (Merck, 465-65-6), and atropine 10 μg (Merck, 51-55-8) were administered 30 minutes before the pentazocine (Merck, 359-83-1)-neostigmine (Merck, 114-80-7) mixture.

2.2. Drugs. The drugs nor-Binaltorphimine 10 μg, CTAP 10 μg, naloxone 10 μg, atropine 10 μg, pentazocine (3–100 μg), neostigmine (0.3–10 μg), and pentazocine-neostigmine were respectively dissolved in 10 μl of normal saline and were administered intrathecally [17–20]. The antagonists were intrathecally administered as described elsewhere [21].

2.3. Treatment Schedule and Experimental Design. In this study, we designed four independent experiments, and our study established n = 10 rats for each experimental group. All the rats were randomly divided into different groups.

Experiment I: Male SD rats (n = 130) were divided into 13 groups and intrathecally administered (i.t.) 30 minutes before the formalin test with different doses of pentazocine (3 μg, 10 μg, 30 μg, and 100 μg, i.t., n = 10), neostigmine (0.3 μg, 1 μg, 3 μg, and 10 μg, i.t., n = 10), or the pentazocine-neostigmine mixture (1/2ED50, 1/4ED50, 1/8ED50, and 1/16ED50, i.t., n = 10) (Figure 1(a)).

Experiment II: Male SD rats (n = 130) were divided into 13 groups and intrathecally administered (i.t.) 4 hours after a plantar incision model with different doses of pentazocine (3 μg, 10 μg, 30 μg, and 100 μg, i.t., n = 10), neostigmine (0.3 μg, 1 μg, 3 μg, and 10 μg, i.t., n = 10), or the pentazocine-neostigmine mixture (1/2ED50, 1/4ED50, 1/8ED50, and 1/16ED50, i.t., n = 10) (Figure 1(b)).

Experiment III: Male SD rats (n = 120) were divided into 12 groups and several antagonists were intrathecally administered (i.t.) 30 minutes after the administration of the pentazocine (30 μg)-neostigmine (3.0 μg) mixture. Saline alone (10 μl), nor-Binaltorphimine (10 μg), CTAP (10 μg), naloxone (10 μg), and atropine (10 μg), were intrathecally administered 30 minutes before the administration of the pentazocine (30 μg)-neostigmine (3.0 μg) mixture in the formalin test and incision pain model (Figure 1(c)).

2.4. Intrathecal Injection. Under isoflurane (1–3%) inhalation anesthesia, a sterile needle attached to a 25 μl micro-injector was inserted into the intervertebral space between
L5 and L6 in rats. A sudden and slight flick of the tail indicated that the needle entered the subarachnoid space, where 10 μl of the specific therapeutic drug or vehicle was delivered for more than 30 seconds [21]. The needle was held in the same position for an additional 15 seconds to ensure diffusion prior to removal. Thirty minutes after intrathecal injection the behavioral tests were performed.

2.5. The Formalin Test. A 30-gauge needle was used to inject 50 μl of 5% formalin subcutaneously into the plantar surface of the left hind paw [17]. Next, the rats were placed in a transparent organic glass cylinder (20 cm × 30 cm) for observation. A mirror was placed under the cylinder at a 45° angle. Immediately after injection, the rat exhibited the behavioral plantar pain phenomenon exhibiting spontaneous flinching, withdrawing, and licking of the injected paw. Pain behavior was quantified by recording the number of paw flinches for 1-minute periods from 1 to 2 minutes and 5 to 6 minutes and then at 5-minute intervals between 10 minutes and 60 minutes after the formalin injection. We observed two phases of paw flinching behavior. The first stage in the pain model (the interval between 0 and 6 minutes after the formalin injection) is the initial acute pain response, followed by the second stage, persistent pain (starting about 10 minutes after the formalin injection).

2.6. The Plantar Incision Model. In order to simulate acute postoperative pain, we used the rat plantar incision model [22]. The rats were anesthetized with 2–3% isoflurane. Make a 1 cm longitudinal incision at the plantar surface of the right hind foot 0.5 cm from the heel end. The skin, fascia, and underlying flexor muscles were cut, and the wound was sutured with 5–0 nylon sutures after sufficient hemostasis. The sham control group rats were anesthetized without incision. Four hours after the pain model was established, the rat behavior test was performed.

2.7. Mechanical Allodynia. Mechanical allodynia (other pain) is a painful sensation triggered by an innocuous stimulus, such as a light touch [23]. Rats were placed on a mesh floor individually covered with a clear plastic cage and allowed to acclimate for 30 minutes. Paw withdrawal response to mechanical stimulation was detected by the calibrated von Frey hairs method. Mechanical sensitivity was assessed using the von Frey hairs (0.4 g, 0.6 g, 1 g, 2 g, 4 g, 6 g, 8 g, 10 g, and 15 g) up-down method as previously described [24].

2.8. Isobolographic Analysis. To test the interaction between pentazocine and neostigmine, we performed an isobolo-graphic analysis. First, each ED50 value (effective dose producing a 50% maximal possible effect) was identified by the dose-response curves for each of the two drugs. In the formalin test, the time response data are presented as the number of paw flinches in 1-minute periods from 1 to 2 minutes and 5 to 6 minutes and then at 5-minute intervals between 10 minutes and 60 minutes after the formalin injection. We observed two phases of paw flinching behavior. The first stage in the pain model (the interval between 0 and 6 minutes after the formalin injection) is the initial acute pain response, followed by the second stage, persistent pain (starting about 10 minutes after the formalin injection).

\[
\% \text{MPE} = \frac{\text{Sum of control phase I (II) count} - \text{Sum of phase I (II) count with drug}}{\text{Sum of control phase I (II) count}} \times 100. \quad (1)
\]
In the plantar incision model, the 50% MPE (ED$_{50}$) was calculated using the following formula [25]:

\[
\%\text{MPE} = \left( \frac{\text{Threshold post drug} - \text{Threshold post control}}{\text{Baseline} - \text{Threshold post control}} \right) \times 100.
\] (2)

Next, the respective ED$_{50}$ values (1/2, 1/4, 1/8, and 1/16) for each drug were coadministered. The experimental ED$_{50}$ for the mixture was calculated by the dose-response curves of the mixture. The expected additive ED$_{50}$ values for pentazocine and neostigmine were determined by an isobologram. The x and y axes in the isobologram represent the ED$_{50}$ values of each drug, respectively. The lines connecting the ED$_{50}$ points are the theoretical additive lines and the theoretical additive points for the drug combinations. The experimental values below the lines of additivity indicate a synergistic interaction [25].

2.9. Statistical Analysis. All data were expressed as the means ± SEM. The Shapiro–Wilk test was used to detect the normality of the data distribution. To compare the differences between each dose of pentazocine, neostigmine, and the mixtures of pentazocine and neostigmine in two stages of the formalin test and the von Frey test, we used one-way analysis of variance (ANOVA) or two-way ANOVA followed by the Bonferroni post hoc test. The differences between the experimental ED$_{50}$ for pentazocine, neostigmine, and the mixtures, and the expected additive ED$_{50}$ values for pentazocine, neostigmine, and the mixtures were evaluated by the one-way ANOVA in the formalin test and the von Frey test. The criterion for statistical significance was a P < 0.05. Statistical tests were performed with SPSS 21.0 software (SPSS, USA).

3. Results

3.1. The Effects of Pentazocine and Neostigmine on Formalin-Induced Pain. The number of flinches for each minute is plotted versus the time after the formalin injection into the hind paw. Two phases of paw flinching behavior were separately quantified. Intrathecal administration of pentazocine (Pen) and neostigmine (Neo) decreased the number of paw flinches. Pentazocine (3–100 µg) relieved the formalin-induced phase I pain (one-way ANOVA, F$_{4,45} = 9.990$, P < 0.001) (Figure 2(b)) and phase II pain (one-way ANOVA, F$_{4,45} = 20.675$, P < 0.001) (Figure 2(c)). Neostigmine (0.3–10 µg) also relieved the formalin induced phase I pain (one-way ANOVA, F$_{4,45} = 10.649$, P < 0.001) (Figure 2(e)) and phase II pain (one-way ANOVA, F$_{4,45} = 16.748$, P < 0.001) (Figure 2(f)). In phases I and II, pentazocine’s calculated ED$_{50}$ values were 91.1 ± 5.4 µg and 101.2 ± 6.2 µg, respectively. Neostigmine’s ED$_{50}$ values in phases I and II were 8.93 ± 0.59 µg and 9.2 ± 0.55 µg, respectively (Figures 2(i) and 2(j), Table 1).

3.2. The Effects of Pentazocine and Neostigmine on Plantar Incision-Induced Mechanical Allodynia. Behavior was tested 30 minutes after the intrathecal injection. Intrathecal injection of pentazocine (3–100 µg) produced a dose-dependent inhibition against the plantar incision-induced mechanical allodynia (repeated measure, two-way ANOVA, F$_{4,36} = 29.178$, P < 0.001) (Figure 2(g)). Intrathecal injection of neostigmine (0.3–10 µg) produced a dose-dependent inhibition against the plantar incision-induced mechanical allodynia (repeat measure, two-way ANOVA, F$_{4,36} = 23.751$, P < 0.001) (Figure 2(h)). The calculated ED$_{50}$ values of pentazocine and neostigmine were 98.0 ± 5.5 µg and 10.2 ± 0.55 µg, respectively (Figure 2(k), Table 1).

3.3. Isobolographic Analyses. We used the ED$_{50}$ of pentazocine and neostigmine in phase I to evaluate their interaction in the formalin pain model. The ED$_{50}$ of pentazocine and neostigmine was 91.1 µg and 8.93 µg in phase I, respectively. Intrathecal administration of the pentazocine-neostigmine mixtures (1/2 ED$_{50}$, 1/4 ED$_{50}$, 1/8 ED$_{50}$ and 1/16 ED$_{50}$) decreased the number of paw flinches (Figure 3(a)). In phase I, the pentazocine-neostigmine mixtures relieved the pain induced by formalin (one-way ANOVA, F$_{4,45} = 34.687$, P < 0.001) (Figure 3(b)). In phase II, the pain was relieved by the pentazocine-neostigmine mixtures (one-way ANOVA, F$_{4,45} = 99.844$, P < 0.001) (Figure 3(c)). In the plantar incision pain model, pentazocine ED$_{50}$ was 98 µg and neostigmine ED$_{50}$ was 10.2 µg. Intrathecal administration of the pentazocine-neostigmine mixtures (1/2 ED$_{50}$, 1/4 ED$_{50}$, 1/8 ED$_{50}$, and 1/16 ED$_{50}$) significantly attenuated the mechanical allodynia (repeat measure, two-way ANOVA, F$_{4,36} = 50.640$, P < 0.001) (Figure 3(d)).

The experimental ED$_{50}$ for pentazocine and neostigmine were 30.3 ± 2.5 µg and 2.95 ± 0.3 µg in phase I, respectively (Figure 4(a)). The experimental ED$_{50}$ for pentazocine and neostigmine were 34.4 ± 3.0 µg and 3.1 ± 0.24 µg in phase II, respectively (Figure 4(b)). The expected additive ED$_{50}$ values for pentazocine and neostigmine were 45.9 ± 3.9 µg and 4.47 ± 0.43 µg in phase I, respectively (Figure 4(a)). The expected additive ED$_{50}$ values for pentazocine and neostigmine were 50.8 ± 3.5 µg and 4.58 ± 0.42 µg in phase II, respectively (Figure 4(b)). The experimental values for the pentazocine-neostigmine mixtures decreased significantly (P < 0.05) below the lines of additivity indicating a synergistic effect (Figures 4(a) and 4(b) and Table 1). The experimental ED$_{50}$ for pentazocine and neostigmine were 34 ± 2.2 µg and 3.3 ± 0.27 µg, respectively (Figure 4(c)). The expected additive ED$_{50}$ values for pentazocine and neostigmine were 51.0 ± 3.0 µg and 4.85 ± 0.4 µg, respectively (Figure 4(c)). The experimental values for the pentazocine-neostigmine mixtures decreased significantly (P < 0.05) below the lines of additivity, indicating a synergistic effect (Figure 4(c) and Table 1).

3.4. Intrathecal Antagonist Test. We used the selective κ-opioid receptor antagonist nor-Binaltorphimine (10 µg, nor-BNI), the selective μ-opioid receptor antagonist CTAP (10 µg), the nonspecific opioid receptor antagonist naloxone (10 µg), and the muscarinic acetylcholine receptor antagonist atropine (10 µg) to evaluate the possible synergistic effect mechanisms between pentazocine and neostigmine.
Figure 2: Continued.
Figure 2: (a-f). Intrathecal injection of pentazocine (3–100 μg) and neostigmine (0.3–10 μg) induced a dose-dependent inhibition against the formalin-induced pain responses in both phases. (g-h). Injecting pentazocine or neostigmine attenuated the plantar incision-induced mechanical allodynia. (i-k). Dose-response curves of intrathecal pentazocine and neostigmine for flinching during phase I (i) and phase II (j) in the formalin test (k). Data are expressed as the maximal possible effect (% MPE). Each point on the graph represents the mean ± SEM. Compared with the saline group, *P < 0.05, **P < 0.01, ***P < 0.001, n = 10 rats in each group.)
Nor-BNI, naloxone, and atropine, but not CTAP, attenuated the analgesic effect of the pentazocine-neostigmine mixture against formalin-induced pain (Figures 5(a) and 5(b)) and the plantar incision-induced mechanical allodynia (Figure 5(c)).

4. Discussion

The results show that pentazocine and neostigmine produce analgesic effects against formalin-induced pain and incision-induced mechanical allodynia. There was a synergistic effect between pentazocine and neostigmine in both pain models. The formalin test was chosen as it is a valuable method for studying nociception in detecting drug analgesic effects [26]. The test showed a biphasic pain response. The early phase (0–6 minutes, Phase I) was mainly caused by the activation of C-fiber due to the peripheral stimulus, while the late phase (10–60 minutes, Phase II) was caused by an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord [26]. In order to evaluate the analgesic effects of pentazocine and neostigmine in the postoperative period, we used the plantar incisional pain model [22].

As a mixed opioid agonist/antagonist, pentazocine's analgesic mechanism is not entirely understood. The spinal μ- and κ-opioid receptors are considered the most important pathways mediating the analgesic effects of pentazocine [27]. Different administration methods and dosages are also important factors that affect its analgesic actions. The analgesic mechanism of pentazocine varies with different doses and administrations [27]. Its analgesic action shows a biphasic bell-shaped dose-response curve. Intravenous injection of pentazocine at a modest dose (30 mg/kg) exhibits a peak antinociceptive effect via the μ- and κ-opioid receptors [27]. When an intravenous injection of pentazocine reaches a dose of 100 mg/kg, its analgesic effect is mainly through the μ-opioid receptor, not the κ-opioid receptor, as this analgesic effect can be partly antagonized by the κ-opioid receptor agonist [27]. α-adrenergic receptors might be other analgesic pathways of pentazocine as phenolamine alone is effective in reducing pentazocine's analgesic effects [28]. Nor-BNI is a highly selective kappa-opioid receptor antagonist that can partially antagonize the action of morphine and fentanyl [29]. In our results, the synergistic effects between pentazocine and neostigmine can be antagonized by the nonselective opioid receptor antagonist naloxone and the κ-opioid receptor antagonist nor-BNI, but not antagonized by the μ-opioid receptor antagonist CTAP. CTAP is a highly selective antagonist for μ-opioid receptors over δ- and κ-opioid receptors [30]. This shows that the combined medication of this dose is mostly via the κ-opioid receptor, but not the μ-opioid receptor, when intrathecally administered.

Systemic and spinal administration of acetylcholinesterase inhibitors and muscarinic receptor agonists can produce an analgesic effect [9, 12, 15]. Intrathecal injection of neostigmine and physostigmine produces dose-dependent antinociception effects and relieves allodynia in a dose-related manner [9, 12, 15]. The analgesic effect caused by neostigmine is mainly related to the release of acetylcholine and the activation of the muscarinic-acetylcholine receptor, as atropine blocks the muscarinic-acetylcholine receptor and antagonizes the analgesic effect [9, 12, 15]. However, when neostigmine is used as a nondepolarizing muscle relaxant antagonist, it is always used in combination with atropine as it antagonizes the muscarinic-acetylcholine receptor activity [13]. Normally, it inhibits acetylcholinesterase (AchE) and causes more ACh at sites of cholinergetic transmission. ACh is released when physiological stimuli (pain) modulate the processing of pain at the spinal cord or brain stem level [11].

The administration of muscarinic receptor agonists and acetylcholinesterase inhibitors in the spinal cord can also result in antinociception [31]. The perioperative administration of physostigmine can reduce opioid consumption and peri-incisional mechanical allodynia [12]. Intrathecal neostigmine alone, or combined with clonidine, or opioids, has been successfully used for postoperative analgesic effects and pain relief [32], as it produces a longer effect with greater

| Table 1: ED_{50} and SEM for intrathecally administered pentazocine, neostigmine and in combination in a fixed-dose ratio. |
|---|---|---|---|---|---|
| Group | Drug | Pentazocine component | Neostigmine component | Sum of ED_{50} fractions |
| | | Intrathecal dose (μg) | Fraction of ED_{50} | Intrathecal dose (μg) | Fraction of ED_{50} | |
| Formalin test Phase I | PEN | 91.1 ± 5.4 | 1.00 | ---- | ---- | |
| Formalin test Phase II | NEO | ---- | ---- | 8.93 ± 0.59 | 1.00 | 1.00 |
| Plantar incision model | PEN | 101.2 ± 6.2 | 1.00 | ---- | ---- | |
| | NEO | 98.0 ± 5.5 | 1.00 | ---- | ---- | |
| | | | | 10.2 ± 0.55 | 1.00 | 1.00 |
| Formalin test Phase I | PEO + NEO | 30.3 ± 2.5 | 0.33 | 2.95 ± 0.30 | 0.33 | 0.66 |
| Formalin test Phase II | PEO + NEO | 34.4 ± 3.0 | 0.34 | 3.10 ± 0.24 | 0.34 | 0.68 |
| Plantar incision model | PEO + NEO | 34.0 ± 2.2 | 0.35 | 3.31 ± 0.27 | 0.32 | 0.67 |

PEN = Pentazocine; NEO = Neostigmine.
cardiovascular system reliability and fewer side effects. Epidural administration of neostigmine can prolong ropivacaine analgesia and reduce hourly ropivacaine consumption [33]. Intra-articular administration with a 500 μg dose of neostigmine is as effective as a postoperative analgesic and is not likely to significantly increase the adverse effects [11]. The sustained analgesic effects of neostigmine after surgery are also interpreted as a decrease in the activation of the descending pathway of pain-induced acetylcholine release [34]. In our results, the synergistic effects between pentazocine and neostigmine were antagonized by the muscarinic acetylcholine receptor antagonist atropine, indicating that the muscarinic acetylcholine receptor might also be an important pathway for pentazocine-neostigmine’s synergistic analgesic effect. The analgesic effect of intrathecal pentazocine and neostigmine may involve the pain descending inhibitory system. Pentazocine through the opioid and σ-receptor-independent pathway inhibits the norepinephrine transporter function and regulates the descending noradrenergic inhibitory system [35]. Previous works have identified that the spinal nicotinic acetylcholine receptors also affect pain regulation via the descending noradrenergic pathway [36]. We speculate that the descending inhibitory system might be another important pathway for the synergistic effect of pentazocine and neostigmine in formalin-induced pain and incision pain. Different doses of opioid receptor antagonists have different effects [37], and different types of opioid receptors show different effects in relieving thermal allodynia and mechanical pain [27]. This is the main research limitation of our work as we only used one antagonist dose and only two animal models.

Figure 3: (a-c). Intrathecal administration of the pentazocine-neostigmine mixtures attenuated the number of paw flinches in the formalin pain model. (d). Intrathecal administration of the pentazocine-neostigmine mixtures attenuated the mechanical allodynia in the plantar incision pain model. Each bar represents the mean ± SEM from 10 rats. Compared with the saline group, *P < 0.05, **P < 0.01, ***P < 0.001, n = 10 rats in each group.
Figure 4: Shows the interaction between intrathecal pentazocine and neostigmine in phases I (a) and II (b) of the formalin tests and the plantar incisional pain model (c) which were analyzed using an isobologram. The x- and y-axes represent the ED$_{50}$ dose of pentazocine and neostigmine, respectively. The lines connecting the ED$_{50}$ points are the theoretical additive lines and the theoretical additive points for the drug combinations. The theoretical additive value was significantly higher than the experimental ED$_{50}$ value of the combination of the two drugs. The experimental ED$_{50}$ values were significantly below the lines of additivity, indicating a synergistic interaction.

Figure 5: Continued.
We used isobolographic analysis to demonstrate the synergistic interaction between intrathecal pentazocine and neostigmine in both phases of the formalin test and the plantar incision model. There are several possibilities for this synergistic effect. Synergistic effect occurs when drugs have different effects at critical points along a common pathway [38]. Here, the cholinesterase inhibitor modulates the transmission and processing of nociception according to the pre- and postsynaptic mechanisms, so simultaneous engagement of pre- and postsynaptic mechanisms may enhance the antinociception induced by either drug acting at one site independently [9, 16]. Moreover, two different receptors can simultaneously activate a common second messenger pathway in a single neuron and promote an effector mechanism [38, 39]. In this present study, the combined therapy of pentazocine and neostigmine produced a dose-dependent analgesic against formalin-induced pain and incisional mechanical allodynia. The combined use of pentazocine and neostigmine has a synergistic effect which may be related to the cholinergic system and the κ-opioid receptor at the spinal cord level.

**Data Availability**

All the original data can be obtained from the corresponding author of the article by e-mail (ouyhd@sysucc.org.cn).

**Disclosure**

Huiying Huang, Xiaohui Bai, Kun Zhang are the co-first authors.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Huiying Huang, Xiaohui Bai, Kun Zhang contributed equally to this work. Shaoyong Wu and Handong Ouyang are co-corresponding authors. H. H., X. B., and H. O conceptualized the data, X. B., K. Z., S. W., and J. G. curated the data, H. O. did the supervision, H. H. and X. B. performed the data analysis. X. B. and H. O. wrote the original draft of the article.

**Acknowledgments**

The authors would also like to thank Mr. Christopher Lavender of Sun Yat-sen University Cancer Center’s in-house Editorial Officer for the language editing of this article. This work was supported by the National Natural Science Foundation of China (82071237 and 81771192) and H. O.’s Clinical Medical Scientists Project of Sun Yat-sen University Cancer Center (PT09090101).

**References**

[1] P. J. Fudala and R. E. Johnson, “Development of opioid formulations with limited diversion and abuse potential,” *Drug and Alcohol Dependence*, vol. 83, no. Suppl 1, pp. S40–S47, 2006.

[2] S. J. Mahapatra, S. Jain, S. Bopanna et al., “Pentazocine, a kappa-opioid agonist, is better than diclofenac for analgesia in acute pancreatitis: a randomized controlled trial,” *American Journal of Gastroenterology*, vol. 114, no. 5, pp. 813–821, 2019.

[3] T. Mori, J. Ohya, T. Itoh, Y. Ise, M. Shibasaki, and T. Suzuki, “Effects of (+)-pentazocine on the antinociceptive effects of (-)-pentazocine in mice,” *Synapse*, vol. 69, no. 3, pp. 166–171, 2015.

[4] J. L. Riley, B. A. Hastie, T. L. Glover, R. B. Fillingim, R. Staud, and C. M. Campbell, “Cognitive-affective and somatic side...
effects of morphine and pentazocine: side-effect profiles in healthy adults,” *Pain Medicine*, vol. 11, no. 2, pp. 195–206, 2010.

[5] M. Hirabayashi, K. Doi, N. Imamachi, T. Kishimoto, and Y. Saito, “Prophylactic pentazocine reduces the incidence of pruritus after cesarean delivery under spinal anesthesia with opioids: a prospective randomized clinical trial,” *Anesthesia & Analgesia*, vol. 124, no. 6, pp. 1930–1934, 2017.

[6] D. L. Robinson Jr., S. Nag, and S. S. Mokha, “Estrogen facilitates and the kappa and mu opioid receptors mediate antinociception produced by intrathecal (-)-pentazocine in female rats,” *Behavioural Brain Research*, vol. 312, pp. 163–168, 2016.

[7] N. Massaly, B. A. Copits, A. R. Wilson-Poe et al., “Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system,” *Neuron*, vol. 102, no. 3, pp. 564–573 e6, 2019.

[8] V. Tiwari, S. Q. He, Q. Huang et al., “Activation of μ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents,” *Pain*, vol. 161, no. 4, pp. 842–855, 2020.

[9] P. V. Naser and R. Kuner, “Molecular, cellular and circuit basis of cholinergic modulation of pain,” *Neuroscience*, vol. 387, pp. 135–148, 2018.

[10] Z. Y. Wang, Q. Q. Han, M. Y. Deng et al., “Lemairamin, isolated from the Zanthoxylum plants, alleviates pain hyperalgesia in rats,” *Pain Research and Management*, vol. 387, pp. 135–148, 2018.

[11] A. S. Habib and T. J. Gan, “Use of neostigmine in the management of acute postoperative pain and labour pain: a review,” *CNS Drugs*, vol. 20, no. 10, pp. 821–839, 2006.

[12] C. Klivinyi, G. Rumpold-Seitlinger, C. Dorn et al., “Perioperative use of physostigmine to reduce opioid consumption and peri-incisional hyperalgesia: a randomised controlled trial,” *British Journal of Anaesthesia*, vol. 126, no. 3, pp. 700–705, 2021.

[13] A. Sen, B. Erdívani, Y. Tomak, and A. Pergel, “Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine: effect on postoperative gastrointestinal motility,” *Journal of Clinical Anaesthesia*, vol. 32, pp. 208–213, 2016.

[14] T. K. Oh, E. Ji, and H. S. Na, “The effect of neuromuscular reversal agent on postoperative pain after laparoscopic gastric cancer surgery: comparison between the neostigmine and sugammadex,” *Medicine*, vol. 98, no. 26, p. e16142, 2019.

[15] J. Eldufani and G. Blaise, “The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications,” *Alzheimer’s and Dementia: Translational Research & Clinical Interventions*, vol. 5, no. 1, pp. 175–183, 2019.

[16] D. Radzicki, S. L. Pollema-Mays, A. Sanz-Clemente, and M. Martina, “Loss of M1 receptor dependent cholinergic excitation contributes to mPFC deactivation in neuropathic pain,” *Journal of Neuroscience*, vol. 37, no. 9, pp. 2292–2304, 2017.

[17] T. Yamamoto, O. Saito, K. Shono, and S. Tanabe, “Anti-hyperalgesic effects of intrathecally administered neuropeptide W-23, and neuropeptide B, in tests of inflammatory pain in rats,” *Brain Research*, vol. 1045, no. 1-2, pp. 97–106, 2005.

[18] K. A. Ahmad, R. M. Shoab, M. Z. Ahsan et al., “Microglial IL-10 and beta-endorphin expression mediates gabapentinoids antineuropathic pain,” *Brain, Behavior, and Immunity*, vol. 95, pp. 344–361, 2021.
acetylcholine concentrations in the adult rat brain: a meta-analysis,” *Synapse*, vol. 66, no. 10, pp. 893–901, 2012.

[35] G. Obara, Y. Toyohira, H. Inagaki et al., “Pentazocine inhibits norepinephrine transporter function by reducing its surface expression in bovine adrenal medullary cells,” *Journal of Pharmacological Sciences*, vol. 121, no. 2, pp. 138–147, 2013.

[36] D. Bagdas, G. Sevdar, Z. Gul et al., “(E)-3-furan-2-yl-N-phenylacrylamide (PAM-4) decreases nociception and emotional manifestations of neuropathic pain in mice by α7 nicotinic acetylcholine receptor potentiation,” *Neurological Research*, vol. 43, no. 12, pp. 1056–1068, 2021.

[37] C. Stein, “Opioid receptors,” *Annual Review of Medicine*, vol. 67, no. 1, pp. 433–451, 2016.

[38] A. Alcantara Montero, S. Balsalobre Gongora, D. M. Narganes Pineda, and B. Blanco Polanco, “Multimodal analgesia and pharmacological synergy in pain management,” *SEMERGEN-Medicina de Familia*, vol. 46, no. 4, pp. 284–285, 2020.

[39] N. P. Kazantzis, S. L. Casey, P. W. Seow, V. A. Mitchell, and C. W. Vaughan, “Opioid and cannabinoid synergy in a mouse neuropathic pain model,” *British Journal of Pharmacology*, vol. 173, no. 16, pp. 2521–2531, 2016.